140 related articles for article (PubMed ID: 31338800)
1. Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults.
Wu L; Liu J; Zheng Y; Zhai Y; Lin M; Wu G; Lv D; Shentu J
Clin Drug Investig; 2019 Oct; 39(10):953-965. PubMed ID: 31338800
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
[TBL] [Abstract][Full Text] [Related]
4. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
[TBL] [Abstract][Full Text] [Related]
6. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
[TBL] [Abstract][Full Text] [Related]
8. Development of Dexlansoprazole Delayed-Release Capsules, a Dual Delayed-Release Proton Pump Inhibitor.
Grady H; Murakawa Y; Mulford D; Kukulka M
J Pharm Sci; 2019 Nov; 108(11):3496-3501. PubMed ID: 31386865
[TBL] [Abstract][Full Text] [Related]
9. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
Zhang W; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
[TBL] [Abstract][Full Text] [Related]
10. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
Vakily M; Wu J; Atkinson SN
J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
[TBL] [Abstract][Full Text] [Related]
11. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H
Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
[TBL] [Abstract][Full Text] [Related]
12. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
13. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
Abbas R; Leister C; Sonnichsen D
Clin Drug Investig; 2013 Aug; 33(8):589-95. PubMed ID: 23839484
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of the effect of PO administered acid suppressants on gastric pH in healthy cats.
Ryan P; Odunayo A; Price J; Hecht S; Hillsman S; Galyon G; Steiner J; Tolbert MK
J Vet Intern Med; 2020 Sep; 34(5):1879-1885. PubMed ID: 32885499
[TBL] [Abstract][Full Text] [Related]
15. Greater immediate gastric acid suppression with lansoprazole 30 mg administered as a 2-minute intravenous bolus injection versus a 30-minute infusion.
Metz DC; Devlin JW; Vakily M; Atkinson S; Lloyd E
Pharmacotherapy; 2008 Mar; 28(3):301-7. PubMed ID: 18294109
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.
Zhang D; Zhang Y; Liu M; Wang X; Yang M; Han J; Liu H
Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):209-15. PubMed ID: 23229306
[TBL] [Abstract][Full Text] [Related]
18. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
[TBL] [Abstract][Full Text] [Related]
19. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
20. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
Metz DC; Vakily M; Dixit T; Mulford D
Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]